Condition category
Circulatory System
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Plain English Summary

Background and study aims
The current definition of delayed cerebral ischemia (DCI) is based on clinical characteristics and limited to awake patients. This largely precludes the use in poor-grade subarachnoid hemorrhage (SAH) patients, creating the need for additional parameters to evaluate the unconscious patient. Invasive neuromonitoring (INM) allows for continuous registration of brain metabolic functioning and may enable timely detection of metabolic crises in high-grade SAH patients. The aim of this trial is to analyze the effects introducing INM as a diagnostic tool on clinical decision-making, applied treatment and eventually, clinical outcome.

Who can participate?
All patients referred to a single tertiary care center between 2010 and 2018 with an aneurysmal subarachnoid hemorrhage.

What does the study involve?
The study has an observational design. It involves the comparison of two groups of similar patients, one in which INM was available and one in which it was not available as a diagnostic tool. Both cohorts are separated in time creating potential selection and information bias for which cannot be actively corrected. We will rigorously compare groups for any differences in baseline characteristics to exclude most relevant selection bias.

What are the possible benefits and risks of participating?
We anticipate that invasive neuromonitoring contributes to early identification of patients suffering delayed cerebral ischemia and selecting those who will profit from treatment faster. If this is the case, earlier treatment initiation in the appropriate selected patient can contribute to better outcome. Invasive monitoring carries however some potential procedural risks e.g. infection, hemorrhage and technical difficulties leading to false measurements.

Where is the study run from?
The study is run and performed and the neurointensive care unit of the department of neurosurgery at the university hospital in Aachen, Germany.

When is the study starting and how long is it expected to run for?
The trial has started in January 2014 and ended in December 2018.

Who is funding the study?
The trial is funded by the university hospital Aachen, Germany.

Who is the main contact?
Dr. Michael Veldeman

Trial website

Contact information



Primary contact

Dr Michael Veldeman


Contact details

Pauwelstrasse 30

Additional identifiers

EudraCT number

Nil known number

Nil known

Protocol/serial number


Study information

Scientific title

The effectiveness of invasive neuromonitoring in high-grade subarachnoid hemorrhage patients - a prospective cohort study



Study hypothesis

Invasive neuromonitoring in subarachnoid hemorrhage patients leads to earlier detection of delayed ischemic events. This results in an earlier treatment initiation and potentially in a better patients outcome.

Ethics approval

Approved 17/04/2014, the ethics committee of the university hospital of Aachen (Pauwelstrasse 30, 52064 Aachen, Germany; +49/241.80.89963;

Study design

The study has been designed as a part retrospective, part prospective cohort trial.

Primary study design


Secondary study design

Case-control study

Trial setting


Trial type


Patient information sheet

No participant information sheet available


Delayed cerebral ischemia occurring after subarachnoid hemorrhage.


This being an observational trial, all patients are treated according to the hospitals/departments standard operating procedure. We are comparing two historical groups of which data has been collected prospectively. Starting in 2014, invasive monitoring for delayed cerebral ischemia became available in our neuro-intensive care unit. This means that eligible patients, with a poor-grade subarachnoid hemorrhage were considered for placement of monitoring probes. In this case, a small surgical procedure was performed in which two measurement probes were implanted in the left or right frontal lobe. This procedure is part of our standard of care. The goal of this observational analysis is to investigate whether this additional diagnostic procedure contributed to more adequate and effective treatment of delayed cerebral ischemia.

Intervention type



Phase III

Drug names


Primary outcome measure

Clinical outcomes as measured using the extended Glasgow outcome scale after 12 months. Data is collected prospectively during regular follow-ups and missing information is either appended by analysis of patients files or a structured telephone interview by a blinded assessor.

Secondary outcome measures

1. GOS-E at discharge; GOS-E at 6 months measured and evaluated as mentioned above.
2. Overall mortality.
3. The lag between ictus and first treatment triggering DCI event (days), as is clear from patients files.
4. The absolute number of CT investigations performed during the DCI time frame, in every patient. This as an indirect measurement of reliance in clinical decision making, on the measurements made by the invasive monitoring.
5. The prevalence of silent infarctions (the occurrence of a demarcated infarction as the first sign of ongoing DCI). This is measured by investigation of patients CT and/or MRI images by a blinded observer.
6. The prevalence of overall DCI related infarction as is apparent in clinical files and medical imaging.
7. The prevalence of DCI related mortality, as is apparent in clinical files.

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Suffered an aneurysmal subarachnoid hemorrhage.
2. Aged between 18 and 99 years old.
3. The hemorrhage has to present with a Hund & Hess grade of 3 or higher.

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. The occurrence of early angiographical vasospasms in the first diagnostic angiography.
2. Subarachnoid hemorrhage not cause by aneurysm rupture.

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

University Hospital Aachen, Germany
Pauwelstrasse 30 52074 Aachen Germany

Sponsor information


University Hospital Aachen

Sponsor details

Pauwelstraße 30ss

Sponsor type




Funder type


Funder name

University Hospital Aachen

Alternative name(s)

Funding Body Type

Funding Body Subtype


Funder name

RWTH Aachen University

Alternative name(s)

Rhine-Westphalia Institute of Technology Aachen, RWTH Aachen, Rheinisch-Westfälische Technische Hochschule Aachen

Funding Body Type

private sector organisation

Funding Body Subtype

Universities (academic only)



Results and Publications

Publication and dissemination plan

After statistical analysis, date should be ready for publication near the beginning of 2020.

IPD sharing statement: Date is stored on a centralized databank stored on the server of the medical faculty of the university of Aachen. There is no web link as the data can only be accessed via our institutional intranet. Only members of the vascular research team of the department of neurosurgery, have access to these data. After completion of the data sheets, patient names and other identifiers are replaced by a single patient identification code.

Anonymized raw data can be made available on demand to researcher who are have appropriate qualifications. Whether to provide the data will remain an individual decision of our research team. The raw data consists out of spreadsheets in .xslx format. This data can be used for redo statistics or additional analyses.

Intention to publish date


Participant level data

Available on request

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

12/08/2019: Trial's existence confirmed by the Ethics Committee at the RWTH Aachen Faculty of Medicine.